Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. develops and commercializes biopharmaceutical products built around tenapanor and NHE3 inhibition. The company has two U.S.-approved commercial products: IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH to reduce serum phosphorus in adults with chronic kidney disease on dialysis when phosphate binder therapy is inadequate or not tolerated.
Ardelyx news commonly covers product revenue, prescription trends, business updates, scientific meeting presentations, and clinical analyses tied to XPHOZAH and IBSRELA. Recurring developments also include pipeline work in chronic idiopathic constipation and next-generation NHE3 inhibition, commercialization with partners outside the United States, patient advocacy programs, and executive leadership changes in medical, legal, finance, and compliance functions.
Ardelyx, Inc. (Nasdaq: ARDX) has announced that CEO Mike Raab will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 8:30 a.m. ET in New York City. The event aims to showcase Ardelyx's innovative biopharmaceutical developments, including its approved product IBSRELA and the candidate XPHOZAH, which targets serum phosphorus control in CKD patients. A live webcast of the presentation will be available on the company’s investor website, with a replay accessible for 30 days.
On May 24, 2022, Ardelyx presented new data on IBSRELA from Phase 3 trials T3MPO-1 and T3MPO-2 at the Digestive Disease Week Conference. The presentations highlighted IBSRELA's safety and efficacy in adults with irritable bowel syndrome with constipation (IBS-C). Results showed significant symptom relief, treatment satisfaction, and quality of life improvements compared to placebo. IBSRELA is FDA-approved for treating IBS-C and offers a novel mechanism for addressing this condition, impacting millions in the US.
Ardelyx, Inc. (Nasdaq: ARDX) announced that new data highlighting the efficacy and safety of IBSRELA will be presented at the 2022 Digestive Disease Week Conference from May 21-24, 2022. Key presentations include findings on long-term treatment with Tenapanor for IBS-C and its impact on patient satisfaction and early onset of action. Additionally, Ardelyx is sponsoring a Product Theater featuring expert discussions on IBSRELA’s innovative treatment approach and trial efficacy data. Safety warnings for pediatric use are emphasized due to dehydration risks.
Ardelyx, Inc. (Nasdaq: ARDX) announced that new data showcasing the efficacy and safety of IBSRELA (tenapanor) will be presented at the 2022 Digestive Disease Week Conference (DDW) from May 21-24 in San Diego, California. The presentations include three posters focusing on long-term treatment benefits and patient quality of life. Additionally, Ardelyx will sponsor a Product Theater on May 23, discussing IBSRELA's innovative approach in treating Irritable Bowel Syndrome with Constipation (IBS-C). IBSRELA is indicated for adults and has demonstrated promise in improving symptoms.
On May 16, 2022, Ardelyx, Inc. (NASDAQ: ARDX) announced the granting of stock options and Restricted Stock Units (RSUs) to new non-executive employees as part of their employment inducements. A total of 26,953 stock options and 29,250 RSUs were granted, with each stock option priced at $0.72, the company's closing stock price on the grant date. The options vest over four years, while RSUs follow a similar vesting schedule. Ardelyx continues its mission to develop innovative medicines, with ongoing programs targeting significant medical needs.
Ardelyx, Inc. (Nasdaq: ARDX) reported its first quarter 2022 results, showing a cash position of $89.7 million, down from $116.7 million in Q4 2021. The company recognized $0.5 million in product sales from IBSRELA, its first FDA-approved product for IBS-C. Collaboration revenue decreased to $18,000 from $6.6 million year-over-year. R&D expenses fell by 56.7% to $8.9 million, while SG&A expenses rose 12.9% to $19.3 million. The net loss for Q1 2022 was $28.1 million ($0.21 per share), an improvement from a $33.2 million loss in Q1 2021. A conference call was scheduled for 4:30 PM ET today.
Ardelyx, Inc. (NASDAQ: ARDX) will hold a conference call on May 5, 2022, at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update. The company, focused on developing innovative medicines, has completed three successful Phase 3 trials for its product candidate XPHOZAH (tenapanor) designed to control serum phosphorus in CKD patients on dialysis. Ardelyx is also advancing treatments for potassium management and metabolic acidosis, with partnered development in Japan, China, and Canada.
Ardelyx announced an interim response from the FDA regarding its appeal for XPHOZAH's New Drug Application (NDA), initially denied in July 2021. The FDA's Office of New Drugs emphasized the need for input from expert clinicians through an Advisory Committee meeting to evaluate the phosphate-lowering effects demonstrated in the Phase 3 trials for XPHOZAH, intended for patients with chronic kidney disease on dialysis. Ardelyx expects a response within 30 days post-meeting.
On April 5, 2022, Ardelyx, Inc. (Nasdaq: ARDX) announced the grant of stock options and Restricted Stock Units (RSUs) to five non-executive employees as an employment inducement. A total of 68,797 stock options and 33,450 RSUs were awarded, with an exercise price of $1.11 per share, equal to the closing trading price on the grant date. Vesting occurs over four years, with 25% vesting annually and the remainder monthly for stock options, while RSUs vest quarterly. This grant aligns with Nasdaq rules and is aimed at incentivizing employee commitment.
On April 11, 2022, Ardelyx, Inc. (Nasdaq: ARDX) announced an amendment to its license agreement with Kyowa Kirin Co. Ltd. concerning tenapanor, intended for treating cardiorenal diseases in Japan. The agreement includes a reduced royalty rate in exchange for a total payment of up to $40 million, contingent on Kyowa Kirin's marketing approval filings. This change will lower the royalty payments from the high teens to mid-single digits over a specified period. Kyowa Kirin plans to file for approval in the second half of 2022 and expects a decision by the second half of 2023.